ProtocolsBack To Search Instructions
10 protocol(s) meet the specified criteria
Disease Site: Acute Myeloid Leukemia
Protocol No.TitleStatus
1718GCCC-S17A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, azacitidine (Aza) and venetoclax (Ven) in newly diagnosed, untreated Acute Myeloid Leukemia (AML) Patients >/= 60 years with NPM1 mutated/FLT3-ITD and FLT3-TKD wild type AML or Mixed Lineage Leukemia (MLL) Gene RearrangementsOpen
1718GCCC-S6A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age >/= 18 yearsOpen
2035GCCC2035GCCC: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)Open
2087GCCC2087GCCC: Pegcrisantaspase in combination with venetoclax for treatment of relapsed or refractory acute myeloid leukemia (R/R AML)Open
2099GCCC2099GCCC: A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients with Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotypic Acute Leukemia (MPAL)Open
2100GCCCPhase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell TransplantOpen
2103GCCC2103GCCC: Phase 1/1b trial of talazoparib and gemtuzumab ozogamicin (GO) in adult patients with relapsed and/or refractory acute myeloid leukemia (I_435819 Roswell Park)Open
21138GCCC21138GCCC: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed Previously Untreated Patients with Acute Myeloid Leukemia who are Ineligible for Intensive ChemotherapyOpen
2189GCCC2189GCCC: A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS)Open
2208GCCC2208GCCC:A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)Open